Hana at buy by Jefferies

Hana Biosciences Inc. was rated at buy by Jefferies & Co., Inc. analyst Adam Walsh. Positive pivotal Zensana data and phase 1 Talotrexin results presented at ASCO made the analyst bullish. Shares of the South San Francisco, Calif.-based biopharmaceutical company were down 14 cents, or 1.52%, at $9.05 on volume of 71,340 shares versus the three-month running average of 198,849 shares. (Nasdaq: HNAB)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.